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Background—We sought to separately examine the effects of either weight loss or diets varying in protein content and glycemic index
without further changes in body weight on cardiovascular risk factors within the Diet, Obesity, and Genes study (DiOGenes).
Methods and Results—DiOGenes is a pan-European controlled dietary intervention study in 932 overweight adults who
first lost body weight on an 8-week low-calorie diet and were then randomized to 1 of 5 ad libitum diets for 26 weeks.
The diets were either high or low protein or high or low glycemic index in 4 combinations or control. Weight loss
(!11.23 kg; 95% confidence interval,!11.54 to!10.92; P"0.001) reduced high-sensitivity C-reactive protein (!1.15
mg/L; 95% confidence interval,!1.30 to!0.41; P"0.001), low- and high-density lipoprotein cholesterol, triglycerides,
and blood pressure. During the 26-week weight maintenance period in the intention-to-treat analysis, the further
decrease of high-sensitivity C-reactive protein blood levels was !0.46 mg/L greater (95% confidence interval, !0.79
to !0.13) in the groups assigned to low-glycemic-index diets than in those on high-glycemic-index diets (P"0.001).
Groups on low-protein diets achieved a !0.25 mg/L greater reduction in high-sensitivity C-reactive protein (95%
confidence interval, !0.59 to !0.17) than those on high-protein diets (P"0.001), whereas lipid profiles and blood
pressure were not differently affected.
Conclusions—This large-scale intervention study clearly separates weight loss from dietary composition–related effects.
Low-glycemic-index carbohydrates and, to a lesser extent, low-protein intake may specifically reduce low-grade inflammation
and associated comorbidities in overweight/obese adults.
Clinical Trial Registration—http://www.clinicaltrials.gov. Unique identifier: NCT00390637.
(Circulation. 2011;124:2829-2838.)
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Dietary composition significantly influences cardiovas-cular risk factors and outcomes under ad libitum (free
access to food/diets and type of nutrients) conditions,
as reported in several observational and intervention
studies.1– 4 Although the role of different types of fat
has been addressed in numerous studies, the roles of
carbohydrate quality and of protein intake are less well
established.
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Although a high glycemic index is related to postprandial
hyperglycemia and a greater release of insulin, which may
lead to an unfavorable impact on other cardiovascular risk
factors,5 a lower glycemic index was correlated with
favorable effects on blood lipids, particularly low-density
lipoprotein cholesterol and triglycerides and a lower level
of high-sensitivity C-reactive protein (hsCRP) as a marker
of low-grade inflammation.6 – 8 hsCRP was shown to cor-
relate with the risk of cardiovascular events and type 2
diabetes mellitus in prospective studies.9,10
Dietary protein improves postprandial satiety,11 and higher
intakes may be associated with improved weight mainte-
nance.12 There is an ongoing controversy about the effects of
dietary protein on glucose metabolism. Several studies
showed that dietary protein, apart from saturated fatty acids,
which may accompany animal protein in meat and cheese,
itself seems to cause insulin resistance in both cross-
sectional13 and experimental studies.14 –16 Other studies
showed that an increased protein content of up to 30% of
energy intake has beneficial effects on postprandial and
fasting plasma glucose concentrations, particularly in insulin-
resistant subjects.17,18 Favorable effects of high-protein intake
on blood pressure and blood lipids were described in subjects
with elevated cardiovascular risk factors,1 but effects on
inflammatory markers were not investigated in large human
studies.
The role of the glycemic index and protein intake on
cardiovascular risk markers in healthy but overweight and
obese subjects under non–energy-restricted conditions has
not been investigated in a large cohort. The design of the Diet,
Obesity, and Genes study (DiOgenes), a multicenter, pan-
European study, imposed an initial weight loss period of at
least 8% of body weight in overweight and obese subjects
followed by a 26-week dietary intervention period serving as
a weight maintenance phase. Four different diets were com-
pared with either high or low glycemic index or protein
content, and an additional healthy diet according to national
guidelines served as a background control. Table 1 shows the
targeted macronutrient composition of the diets. The partici-
pants were provided with commercially available food, reci-
pes, cooking and behavioral advice, and a point-based teach-
ing system to achieve the targeted macronutrient
compositions.19 The primary hypothesis of the study was that
one of these diets may be more beneficial for weight
maintenance after the initial weight loss period than the
others. As recently published, the participants in the low-
glycemic-index/high-protein group were able to maintain
their weight most successfully during the 26-week diet
intervention phase.20
Weight loss is known to be associated with substantial
improvements in blood lipids and inflammatory biomark-
ers.21 Our DiOgenes study design clearly separates effects
from weight loss from those due to different dietary intakes in
the weight maintenance period. Therefore, the aim of the
present study was to investigate whether improvements in
hsCRP, triglycerides, total cholesterol, high-density lipopro-
tein cholesterol, and low-density lipoprotein cholesterol as
well as blood pressure after the initial weight loss period can
be maintained or even further improved with diets differing in
protein content and glycemic index and whether these diets
elicit additional weight loss–independent effects.
Methods
Participants
The study protocol was approved by the local ethical committees of
each center, and all subjects provided written informed consent.
Volunteer families from 8 European countries (Netherlands, Den-
mark, United Kingdom, Greece, Spain, Germany, Bulgaria, and the
Czech Republic) were enrolled from November 2005 to April 2007
by various recruitment strategies. Families (2-parent or single-
parent) who were generally healthy with at least 1 parent overweight
(body mass index !27 kg/m2) and aged "65 years and with at least
1 child aged between 5 and 18 years were eligible for the study.
Exclusion criteria for adults were body mass index #45 kg/m2, liver
or kidney diseases, cardiovascular diseases, diabetes mellitus (type 1
or type 2), special diets/eating disorders, systemic infections/chronic
diseases, cancer within the last 10 years, weight change#3 kg within
the previous 3 months, and other clinical disorders or use of
prescription medication that might interfere with the outcome of the
study. A detailed description of inclusion and exclusion criteria has
been published.19
Study Design
After the first clinical investigation day (pre–low-calorie diet) with
baseline measurements, eligible adults followed an 8-week low-
calorie diet (Modifast, Nutrition et Sante´, France) consisting of 800
kcal/d. In addition, 200 g of vegetables per day was allowed. Weight
loss, compliance, and adverse events were checked at regular
intervals during the low-calorie diet. Adults who achieved a weight
loss of !8% after 8 weeks underwent the second clinical investiga-
tion day (post–low-calorie diet), and the respective family was
randomized to 1 of 5 ad libitum diets differing in protein content and
glycemic index: (1) low protein, low glycemic index; (2) low protein,
high glycemic index; (3) high protein, low glycemic index; (4) high
protein, high glycemic index; and (5) control diet according to
accepted national dietary guidelines. Because we sought to specifi-
cally investigate the effects of low- versus high-glycemic-index diets
as well as low- versus high-protein diets, the control diet served as a
background healthy diet only. At the 8 participating study centers
(Maastricht, Copenhagen, Cambridge, Heraklion, Potsdam, Pam-
plona, Sofia, and Prague), the participating families received dietary
instruction for a 26-week period. Subjects were invited to the clinical
investigation days after at least 10-hour overnight fasts and were
asked to eat normally the day before the respective clinical investi-
gation day (no alcohol consumption or exercise). A detailed descrip-
tion of the study design has been published.19,20,22
Dietary Intervention
Subjects were advised to maintain their achieved weight during the
intervention. All subjects had to complete a 3-day dietary record at
weeks 4 and 26 of the dietary intervention period and were given
careful, intensive, and regular dietary and behavioral guidance in
regard to both the macronutrient composition and the glycemic index
of their diets. The targeted macronutrient compositions are shown in
Table 1. To obtain the correct protein/carbohydrate ratios and
glycemic indexes, a point-based system was developed.19 The
control diet is according to the guidelines of the respective national
associations for nutrition. During the whole intervention period
(including the low-calorie diet), the average amount of plant protein
from total protein intake was 36%, with very small changes over
time: 37% at screening, 36% at week 4, and 36% at week 26 of the
dietary intervention. The urinary nitrogen excretion was measured
to control for adherence to the targeted protein intake. The study
was ad libitum concerning the individual choice of food from
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food lists/recommendations but was carefully controlled concern-
ing the macronutrient composition of the respective diets and
adherence to the dietary protocol. Detailed information on the
strategy to manipulate ad libitum macronutrient intake and
glycemic index has been published.22
Anthropometric Measurements, Blood Pressure,
and Blood Parameters
Detailed descriptions of measurement of anthropometric parameters,
blood pressure, and blood parameters are given in Methods in the
online-only Data Supplement and a recent report of the Diogenes
consortium.19
Statistical Analysis
Detailed information on the statistical analysis is given in Methods
and Table II in the online-only Data Supplement.
In brief, results are presented as mean$SD. Statistical significance
was defined as P"0.05. Statistical significance of changes in hsCRP,
lipid profile parameters, and blood pressure was tested by applying
2-tailed Student t tests for unpaired samples. In the case of hsCRP,
the matching of the diet groups during the low-calorie diet phase was
tested by ANOVA without adjustment.
For hsCRP, triglycerides, and total, high-density lipoprotein, and
low-density lipoprotein cholesterol concentrations as well as blood
pressure, intention-to-treat analyses were performed including data
from all 773 participants who underwent randomization by fitting
linear mixed models, taking into account missing values from
participants who dropped out and missing records.
For a sensitivity analysis on hsCRP data, records from all 773
randomized participants were included. For missing data from
participants who withdrew during the dietary intervention, the
baseline data at the time of randomization were carried forward. The
same model as in the intention-to-treat analysis was calculated.
A completion analysis was performed including all 487 partici-
pants with data available at randomization and at the end of the
intervention. Dietary effects on hsCRP during intervention were
calculated by ANCOVA.
In the case of hsCRP, in which the diet term was significant for the
predicted model (intention-to-treat, sensitivity, and completion anal-
yses), significance between the main effects (glycemic index and
protein) was tested by applying 2-tailed Student t tests for unpaired
samples on the already adjusted model predictors.
The statistical analysis was performed with the use of IBM SPSS
Statistics version 18.0 (IBM, Somers, NY).
Results
Study Progress
A total of 1209 adults (mean age, 41 years; body mass index,
34 kg/m2) were screened. The participant flow through the
study is presented in Figure 1. Of 773 adults who were
randomized to the 5 different diets, 546 completed the study
(71%). Details about dropouts are shown in Results in the
online-only Data Supplement. The characteristics of the
participants of the 5 dietary groups were not significantly
different either at randomization or during the low-calorie
diet phase (Table I in the online-only Data Supplement).
Detailed information about dietary intake is given in the
online-only Data Supplement.
Weight Change
Detailed data on the influence of the different diets on weight
maintenance have been published.20 In brief, the participants
showed a substantial and significant reduction in body weight
during the low-calorie diet phase of the study (!11.23 kg;
95% confidence interval [CI], !11.54 to !10.92; P"0.001).
Only the low-protein, high-glycemic-index diet was associ-
ated with a subsequent weight regain (1.67 kg; 95% CI,
0.48–2.87; P"0.05), whereas in an intention-to-treat analy-
sis, the weight regain was 0.93 kg less in high-protein versus
low-protein diet groups (95% CI, 0.31–1.55; P%0.003) and
0.95 kg less in low-glycemic-index versus high-glycemic-
index groups (95% CI, 0.33–1.57; P%0.003).
Blood Parameters
High-Sensitivity C-Reactive Protein
Before the low-calorie diet phase, hsCRP (mg/L) was slightly
increased compared with routine reference clinical values in
all diet groups (ie, hsCRP #3 mg/L; Table I in the online-
only Data Supplement). The hsCRP values decreased signif-
icantly in all groups during the low-calorie diet period
(low-protein, low-glycemic-index group, !1.41$5.55; low-
protein, high-glycemic-index group, !0.87$3.55; high-
protein, low-glycemic-index group, !1.29$2.84; high-
protein, high-glycemic-index group, !1.23$2.90; control,
!0.92$1.76; unadjusted P"0.001 each; Table I in the
online-only Data Supplement) but did not differ significantly
between diets, demonstrating that the groups were well
matched (unadjusted P%0.703; Table I in the online-only
Data Supplement). The subsequent 26-week randomized
intervention period led to a further decrease in hsCRP, which
appeared to be different in the distinct diet groups (Figure 2
and Table 2).
Intention-to-Treat Analysis
A linear mixed model was fitted. During the dietary intervention,
the decrease in hsCRP of participants in the low-glycemic-index
groups was!0.46 mg/L (95% CI,!0.79 to!0.13) greater than in
the high-glycemic-index groups (P"0.001) and was !0.25 mg/L
(95% CI,!0.59 to!0.17) greater in the low-protein groups than in
the high-protein groups (P"0.001). There was no significant
Table 1. Targeted Composition of Nutritional Intake in the 5 Diet Groups During the 26-Week Diet Intervention Phase
Component
Low Protein High Protein
Control (Healthy) Diet
Low Glycemic
Index
High Glycemic
Index
Low Glycemic
Index
High Glycemic
Index
Protein 10–15 23–28 12–15
Carbohydrate 57–62 45–50 55–63
Difference in glycemic index* 15 points 15 points
Fat 23–28 25–30
Values, except points, are percentages of total energy intake.
*The difference in glycemic index in points is the targeted difference between the low-glycemic-index and the high-glycemic-index diet groups.
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interaction between the low-glycemic-index and the low-protein
groups (Table 3). A summary of all fitted models is shown in Table
II in the online-only Data Supplement.
The low-glycemic-index groups were more likely to
achieve an additional reduction of hsCRP concentration of
#15% of the value at randomization than the high-glycemic-
index groups (odds ratio, 1.57; 95% CI, 1.13–2.17;
P%0.007). By contrast, achieving an additional decrease in
hsCRP #15% by varying the protein content of the diet was
unlikely (low protein: odds, 1.05; 95% CI, 0.79–1.39; high
Figure 1. Organizational chart of participant flow through the study. Participants entering subsequent stages of the study as well as
dropouts are indicated in total and separated by gender. LCD indicates low-calorie diet; f/m, female/male; HP, high protein; LP, low
protein; HGI, high glycemic index; LGI, low glycemic index; CTRL, control, and DI1, diet intervention.
Figure 2. A, Changes of high-sensitivity C-reactive protein (hsCRP) between post–low-calorie diet (week 0) and postintervention (week
26). The values were normalized to post–low-calorie diet. For absolute values, see Tables I and II in the online-only Data Supplement.
B, Changes of hsCRP between post–low-calorie diet (week 0) and postintervention (week 26) for the combined low-glycemic-index
(LGI) diets (HP/LGI and LP/LGI) vs high-glycemic-index (HGI) diets (HP/HGI and LP/HGI) and for the combined high-protein (HP) (HP/
HGI and HP/LGI) vs the low-protein (LP) diets (LP/LGI and LP/HGI).
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protein: odds, 0.87; 95% CI, 0.66–1.15; odds ratio, 1.20; 95%
CI, 0.87–1.66; P%0.267) (Table 3).
Sensitivity Analysis
In the sensitivity analysis, the decrease in hsCRP was !0.33
mg/L (95% CI,!0.65 to!0.02) greater in the low-glycemic-
index versus the high-glycemic-index groups (P"0.001) and,
as well, was !0.13 mg/L (95% CI, !0.45 to 0.19) greater in
the low-protein versus the high-protein groups (P%0.001)
and was therefore similar to that in the intention-to-treat
analysis (Table 3).
Completion Analysis
In the completion analysis, only participants randomized to
the low-glycemic-index diet groups had significantly reduced
hsCRP concentrations after the 26-week intervention period
(low glycemic index/low protein: !0.59 mg/L; 95% CI,
!1.04 to !0.15; low glycemic index/high protein: !0.43;
95% CI, !0.89 to 0.03) (Table 2). ANCOVA confirmed the
significantly different influences on hsCRP among the diets
(P"0.001). The isolated effect on lowering hsCRP was more
pronounced in the low-glycemic-index groups compared with
the high-glycemic-index groups than in the low-protein
groups compared with the high-protein groups (low glycemic
index versus high glycemic index: !0.51 mg/L; 95% CI,
!0.98 to !0.04; P"0.001; low protein versus high protein:
!0.15 mg/L; 95% CI, !0.62 to 0.32; P%0.037) (Table 3).
Lipid Profile
Triglycerides, total cholesterol, high-density lipoprotein cho-
lesterol, and low-density lipoprotein cholesterol decreased
significantly in all groups after the low-calorie diet period
(P"0.001; Figures 3 and 4 and Table I in the online-only
Data Supplement) and increased again significantly during
the 26-week dietary intervention period (P"0.001; Table 2
and Figures 3 and 4). Triglycerides tended to remain lower
than at baseline (Figure 3A and Table 2). High-density
lipoprotein cholesterol also decreased substantially during the
low-calorie diet but then increased to significantly higher
levels than before the low-calorie diet in all dietary groups
(P"0.001) (Figure 4A and Table 2). Despite lower body
weight at the end of the intervention, total cholesterol and
low-density lipoprotein cholesterol returned to the baseline
level after the intervention (Figures 3B and 4B and Table 2).
The total cholesterol/high-density lipoprotein cholesterol ra-
tio decreased significantly during the low-calorie diet period
Table 2. Blood Parameters and Anthropometric Measurements and Unadjusted Changes Between Randomization and Week 26 of
the Diet Intervention Period
Variable
Low Protein High Protein
ControlLow Glycemic Index High Glycemic Index Low Glycemic Index High Glycemic Index
No. of
Participants
Change From
Randomization
to Week 26
No. of
Participants
Change From
Randomization
to Week 26
No. of
Participants
Change From
Randomization
to Week 26
No. of
Participants
Change From
Randomization
to Week 26
No. of
Participants
Change From
Randomization
to Week 26
Blood parameters
hsCRP, mg/L 95 !0.60$2.84* 84 !0.24$2.40 108 !0.58$1.81* 96 0.05$2.26 104 !0.10$2.01
Cholesterol, mmol/L 95 0.70$0.72* 84 0.79$0.87* 107 0.80$0.75* 95 0.64$0.66* 103 0.75$0.71*
High-density lipoprotein,
mmol/L
95 0.23$0.21* 84 0.23$0.26* 107 0.21$0.24* 96 0.20$0.21* 104 0.19$0.21*
Low-density lipoprotein,
mmol/L
93 0.40$0.53* 83 0.52$0.74* 108 0.50$0.63* 95 0.37$0.60* 104 0.47$0.61*
Triglycerides, mmol/L 93 0.13$0.53* 82 0.13$0.52* 107 0.19$0.51* 94 0.14$0.38* 102 0.19$0.41*
Systolic blood pressure,
mm Hg
92 4.47$12.81* 80 5.12$10.67* 105 4.24$14.27* 93 2.72$13.39 101 4.50$12.90*
Diastolic blood pressure,
mm Hg
92 1.01$7.89 80 3.55$7.68* 105 1.94$8.01* 93 0.96$7.99 102 3.49$8.02*
Fasting insulin, mU/L 81 0.79$8.28 69 3.17$9.30* 82 1.56$3.49* 80 1.32$5.23* 85 1.30$3.70
Insulin 120-min OGTT,
mU/L
85 !7.73$31.38* 77 !4.31$32.91 104 !3.02$28.74 90 !7.62$32.01* 98 !3.40$30.36*
Fasting glucose,
mmol/L
92 0.11$0.58 83 0.24$0.46* 103 0.10$0.60 94 0.08$0.71 103 0.14$0.44*
Glucose 120-min OGTT,
mmol/L
85 !1.28$1.84* 79 !0.93$1.75* 102 !1.01$1.73* 88 !1.06$1.79* 98 !0.89$1.65*
Anthropometric measures
Body weight, kg 95 0.27$5.01 84 1.45$5.34* 108 !0.38$6.28 96 0.36$5.41 104 0.55$4.46
Fat-free mass, kg 79 0.80$3.73 67 0.75$5.87 91 0.05$4.41 78 1.79$5.82* 86 1.58$3.83*
Fat mass, kg 79 !0.92$5.54 67 !0.40$4.96 91 !1.00$5.65 78 !0.20$7.52 86 !1.14$4.73*
Waist circumference,
cm
93 0.09$7.07 81 0.89$6.84 104 0.49$6.82 95 !0.07$7.09 103 !0.67$6.45
Hip circumference, cm 93 !0.64$6.54 81 !0.15$6.45 104 !0.46$5.90 95 !0.47$6.23 103 !0.59$5.36
Sagittal diameter, cm 91 0.07$1.60 80 0.15$2.14 102 !0.12$1.98 91 !0.10$2.42 100 0.20$2.35
Values shown are mean$SD. Participants were included in this analysis if they had completed the diet intervention period and had complete records for
high-sensitivity C-reactive protein (hsCRP) at the beginning (randomization) and the end of the diet intervention period. OGTT indicates oral glucose tolerance test.
*Significant changes (Student t test for paired samples, P"0.05).
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but showed no significant change during the 26-week dietary
intervention (data not shown). Furthermore, changes during the
dietary intervention showed no differences between groups in
regard to the lipid profile. Similar to the analysis of hsCRP, we
fitted a linear mixed model for triglycerides, total cholesterol,
high-density lipoprotein cholesterol, and low-density lipoprotein
cholesterol, which showed no significant diet term (P#0.7 for
all parameters). A summary of all fitted models is shown in
Table II in the online-only Data Supplement.
Blood Pressure
Both systolic and diastolic blood pressure decreased signifi-
cantly during the low-calorie diet period and increased again in
all dietary groups during the 26-week intervention period (Fig-
ure 5, Table 2, and Table I in the online-only Data Supplement).
Although there was no obvious difference between groups
in increase of systolic blood pressure during the 26-week
intervention period, the diastolic blood pressure tended to
increase less in the low-protein, low-glycemic-index group
compared with the low-protein/high-glycemic-index group
(1.01$7.89 versus 3.55$7.68 mm Hg). Again, a linear mixed
model failed to reach significance level for the diet term for
both systolic blood pressure (P%0.556) and diastolic blood
pressure (P%0.098). A summary of all fitted models is shown
in Table II in the online-only Data Supplement.
Discussion
This dietary intervention study compared the subsequent
effects of low or high glycemic index and protein content
diets on cardiovascular risk factors in healthy overweight
adults, after a substantial weight loss exceeding 8% of body
weight. The energy-restricted period resulted in an expected
and marked improvement of blood lipids, blood pressure, and
hsCRP as a marker for inflammation.23 Caloric restriction is
known to be a strong activator of protective metabolic
pathways, thereby leading to lower blood pressure, improved
blood lipids, and reduced inflammatory markers, including
hsCRP.24–28 However, little is known about the effects of
subsequent non–energy-restricted diets varying in protein
content and glycemic index on these end points. Previous
studies comparing different diets under ad libitum conditions
were small and of short duration29,30 or included patients with
other comorbidities such as diabetes mellitus.8 Moreover, the
design of the DiOGenes study allowed a clear separation of
the effects of caloric restriction from those of dietary
composition.
The main outcome of this study was a significant further
decrease of hsCRP after the initial weight loss, which was
observed with the low-glycemic-index diets only and inde-
pendent of protein content and small weight changes (Table 2
and Figure 1A). This might be related to expected reductions
of postprandial glucose levels with low-glycemic-index diets,
with glucose known to stimulate the expression of inflamma-
tory genes by epigenetic mechanisms.27,31,32 Furthermore,
transient increases in glucose induce persistent changes in
histone methylation patterns at promoters of inflammatory
genes,31–34 which is related to glucose-induced mitochondrial
generation of oxygen radicals. Long-term increases in basal
glucose concentrations are associated with both high fastingTa
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insulin concentrations and insulin resistance, which is known
to promote inflammatory processes and an increment of
hsCRP.35
A low-glycemic-index diet was also associated with re-
duced levels of hsCRP in a prospective Canadian study in
subjects with type 2 diabetes mellitus.8 Moreover, a cross-
sectional study in a Dutch population associated a low
glycemic index with lower values of hsCRP.36 Furthermore,
in randomized controlled trials in overweight subjects, it was
shown that diets based on low-glycemic-index carbohydrates
produced better cardiovascular-related outcomes than con-
ventional low-fat diets.37 Otherwise, no significant effects on
hsCRP and other cardiovascular risk factors were observed in
shorter and smaller ad libitum studies combining low glyce-
mic index and weight loss.38
The DiOGenes study goes beyond these observations: All
diets supported the maintenance of reduced hsCRP concen-
trations as achieved by weight loss, with a background of a
healthy, low-fat food pattern that was rich in vegetables and
fruits in all groups. However, a further decrease in hsCRP
was associated with a low glycemic index and, to a lesser
extent, a lower protein intake only. Thus, repeated increases
in postprandial blood glucose related to high-glycemic-index
food components appear to play an important role in modu-
lating hsCRP. The observation that the dietary protein content
influences hsCRP values has not been reported previously.
The effect was small but significant in all analyses, showing
the robustness of this result. The higher protein content
appeared to interfere with a further decrease of hsCRP
compared with the low-protein diet. Since we have also
shown recently that a high-protein diet in comparison with an
isoenergetic carbohydrate-rich diet high in cereal fibers un-
favorably influences whole-body insulin sensitivity in over-
weight and obese participants,16 evidence is accumulating
that high-protein diets may have less favorable metabolic
effects in comparison to high-fiber and/or low-glycemic-
index diets,39 despite their known beneficial effects on weight
loss and blood lipids.
Figure 3. Changes of triglycerides (A) and total cholesterol (B) on the different diets between pre–low-calorie diet (week 8), post–low-
calorie diet (week 0), and postintervention (week 26). LP indicates low protein; LGI, low glycemic index; HGI, high glycemic index; and
HP, high protein.
Figure 4. Changes of high-density lipoprotein (HDL) cholesterol (A) and low-density lipoprotein (LDL) cholesterol (B) on the different
diets between pre–low-calorie diet (week 8), post–low-calorie diet (week 0), and postintervention (week 26). LP indicates low protein;
LGI, low glycemic index; HGI, high glycemic index; and HP, high protein.
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The initial low-calorie diets resulted in decreases of tri-
glycerides, as expected.40–43 The subsequent increase of
triglycerides during the ad libitum food intake did not differ
between the diets and remained below the initial levels. Thus,
neither the glycemic index nor the protein content signifi-
cantly influenced triglyceride levels under these conditions.
Changes in lipids were described in shorter-term studies
that usually were associated with weight loss.21 Remarkably,
a 1-year study of diabetic patients treated with a low-
glycemic-index diet similarly did not observe changes in
triglyceride or cholesterol levels or hemoglobin A1c,8 whereas
cross-sectional studies typically observe an increase of tri-
glycerides with higher glycemic index.44 These associations
thus appear to be related to the overall pattern of nutrition
rather than the glycemic index only. However, improvements
in blood lipids may also be expected because of the weight
loss and the associated metabolic improvements of insulin
resistance. Total and low-density lipoprotein cholesterol de-
creased markedly during the energy-restricted phase and then
increased back to baseline levels and comparably in all
dietary groups, which is in agreement with results from
another long-term study in patients with type 2 diabetes
mellitus.8 By contrast, high-density lipoprotein cholesterol
decreased slightly during the energy-restricted phase of the
study but then increased comparably between groups and
significantly during the diet phase to levels markedly above
those before the low-calorie diet period at the start of the
study, indicating an overall metabolic improvement due to
weight loss and the healthy pattern of nutrition in all dietary
groups. Cross-sectional studies reported higher levels of
high-density lipoprotein cholesterol on low-glycemic-index
diets, which again may be related to the general nutritional
pattern rather than specifically to the low glycemic
index.36,42,44,45
Systolic blood pressure decreased from normal values
during weight loss but then increased to initial levels during
the diet phases with no differences between diets. By con-
trast, diastolic blood pressure decreased during weight loss
but did not return to the initial levels on all diets. Differences
between diets were subtle, and the changes were not associ-
ated with protein content but may have been moderately
influenced by the glycemic index.
Conclusions
In summary, our findings in this large and multinational
cohort further confirm and substantially extend our knowl-
edge regarding an overall benefit of a low-fat, low-glycemic-
index food pattern. High-protein intake did not elicit relevant
unfavorable effects on cardiovascular risk markers. However,
a low-glycemic-index diet supported by a low-protein diet
appears to further reduce hsCRP, and as such low-grade
inflammation, even after a substantial reduction due to weight
loss. These data therefore provide an important argument in
favor of low-glycemic-index diets in obese healthy
individuals.
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CLINICAL PERSPECTIVE
Food components are well known to affect cardiovascular risk, for which blood pressure, triglycerides, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol, and the inflammatory marker C-reactive protein (CRP) are
established biomarkers. In the present randomized, multicenter study, the separate effects of 11 kg weight loss achieved
during an 8-week low-calorie diet as well as a subsequent 26-week intake of diets varying in protein and glycemic index
on these biomarkers were studied. The choice of food was ad libitum but was strictly controlled by nutritional advice
concerning the targeted fat and protein content as well as glycemic index. Expectedly, the initial weight loss significantly
reduced systolic and diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol, and CRP. The subsequent consumption of different low-fat isocaloric diets resulted in moderate increases of
blood lipids and blood pressure, which, however, were independent of the protein content and glycemic index of the diet.
This clearly indicated that the beneficial effects on blood lipids and blood pressure were driven by the weight reduction
itself but not by the dietary composition. In explicit contrast to the other biomarkers, consumption of low-glycemic-index
diets led to a further decrease of CRP compared with high-glycemic-index diets. A low protein content enhanced the
CRP-lowering effect, whereas a high protein content diminished it. Thus, the combination of low glycemic index and low
protein intake appears to be most effective to reduce CRP, an established marker of low-grade inflammation and
cardiovascular risk.
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1 
 
SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
Anthropometric measurements and blood pressure 
Height was measured by using a stadiometer to the nearest 0.5cm and body weight by using 
a calibrated digital balance to the nearest 0.1kg. BMI was calculated by dividing the subject’s 
weight (in kg) by the square of height (in meters). Waist circumference was taken midway 
between the lower rib and iliac crest at the umbilicus and hip circumference was taken at the 
largest circumference in the area around the buttocks (both measurements to the nearest 0.5 
cm with the subject standing and breathing out). Systolic and diastolic blood pressure was 
measured three times by the same trained personnel always between 7:35 and 7:45 AM with 
an automatic device after at least 5 min while resting in a supine position according to WHO 
criteria. The mean value of the last two measurements was used. All measurements were 
performed according to the same standardized operating procedures in all participating 
centres. 
 
Blood parameters 
Blood was collected in SST vacutainers (glucose, lipids, hsCRP, insulin). After centrifugation 
(15 min at 2500 x g, at 22 ºC for gel tubes), plasma and serum were stored at -80 ºC until 
analysis. Analysis of all samples was performed at the Department of Clinical Biochemistry, 
Gentofte University Hospital, Denmark. Serum hsCRP was measured via an 
immunoturbidimetric assay (Roche Diagnostics), with use of monoclonal antibodies to 
hsCRP and a colorimetric assay (Roche Diagnostics), for the COBAS Integra 400 analyzer. 
Fasting insulin concentrations were measured by a solid-phase, two-site chemiluminescent 
immunometric assay (Siemens Medical Solutions Diagnostics, Ballerup, Denmark) for the 
IMMULITE 2500 analyzer. Fasting and OGTT serum glucose were analyzed by colorimetric 
assays (Ortho-Clinical Diagnostics, Johnson & Johnson, Birkerød, Denmark). 
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Fasting serum total cholesterol, HDL cholesterol and triglycerides were measured by routine 
enzymatic assays (Roche Diagnostics, Hvidovre, Denmark) in the COBAS Integra 400 
analyzer. Serum low-density lipoprotein (LDL) cholesterol was calculated from total 
cholesterol, HDL cholesterol and triglycerides by the Friedewald equation.1 Further details on 
methods have been reported elsewhere.2 
 
Power calculation 
The power calculation of the study estimated a sample size under the assumption that after 
the 26-week intervention, the smallest significant (P < 0.05) difference in weight change 
(estimated to 1.0 kg, standard deviation 2.01 kg) would be found between the low GI and the 
high GI diet groups with a power of 97%. It was estimated that a sample of 918 adults would 
be needed to detect a significant difference between the LGI and the HGI groups, assuming 
a dropout rate of 20% during the low calorie diet phase and a subsequent dropout rate of 
15% during the 26-week diet intervention.2 
 
Statistical analysis 
Results are presented as means ± SD. Statistical significance was defined as P<0.05. 
The dropout rates in the different diet groups were calculated by contingency tables and 
Fisher’s exact test, the corresponding odds ratios by logistic regression. 
Statistical significance of changes in hsCRP, parameters of lipid profile and blood pressure 
was tested by applying two-tailed Student’s t-tests for unpaired samples. In case of hsCRP 
the matching of the diet groups during the LCD phase was tested by ANOVA without 
adjustment. 
For the intention-to-treat analysis, data from all participants who underwent randomization 
were included. With respect to possible bias from different dropout rates among the diet 
groups, linear mixed models were fitted by top-down strategy and use of restricted maximum 
likelihood (REML) estimation to evaluate changes in hsCRP, triglyceride, total-, HDL- and 
LDL-cholesterol concentration as well as blood pressure. All outcome variables were 
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reasonably well behaved and showed a continuous and slightly skewed normal distribution. 
The untransformed variables were used for fitting the model since transformation of the 
variables did not result in a change of the respective model or its statistical significance. The 
intention-to-treat analysis gives unbiased results assuming missing data as missing-at-
random.3 This assumption seemed reasonable since missing data resulted both from 
participants dropping out before finishing as well as those finishing the study. In the latter 
case, i.e. missing blood samples, too small blood sample volume to measure all parameters 
or failed measurements were the reason. For the mixed model all available recordings were 
used from participants who were randomized to the intervention under the assumption that 
data of participants who dropped out during intervention followed the same course. Initially, 
the analyses were adjusted for the following covariates: age, BMI and body weight at pre-
LCD, randomization and post-intervention, weight- and BMI-change during LCD and 
intervention, the outcome variable at randomization as well as their interaction terms. 
Furthermore, for the following factors was adjusted: diet group, sex, center type (“shop 
center” or “instruction center”) and center (number of study-center) as well as their 
interactions terms. Statistically not relevant terms were successively excluded by calculation 
of the restricted -2 log likelihood and comparison by F2-test. 
In the final model for the main outcome hsCRP the interactions between age and hsCRP at 
randomization as well as weight and hsCRP at randomization were included as covariates. 
As factors the diet group and the interactions between diet group and center as well as the 
interaction between diet group and sex were included. For missing values predictors were 
calculated by the model in an iteration process. The fitted models for all outcome variables 
regarding included factors, covariates and P-values for the diet-terms are summarized in 
Supplemental Table 2. 
For a sensitivity analysis on hsCRP data, records from all participants who underwent 
randomization were included. The missing data from those participants who withdrew during 
the diet intervention period was filled in by carrying forward the baseline data at the time of 
randomization. The same model as in the intention-to-treat analysis was calculated. 
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A completion analysis was performed including all participants for whom data were available 
at randomization and at the end of the intervention. Effects on hsCRP during intervention 
were calculated by analysis of covariance (ANCOVA) adjusting for the same factors and 
covariates as in the intention-to-treat analysis. 
In case of hsCRP, where the diet term was significant for the predicted model (intention-to-
treat, sensitivity and completion analysis), significance between the main effects (GI and 
protein) was tested by applying two-tailed Student’s t-tests for unpaired samples on the 
already adjusted model predictors. 
The statistical analysis was performed using IBM SPSS Statistics version 18.0 (IBM, 
Somers, NY, USA). 
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Supplemental Results 
Dropout rates 
Between November 2005 and September 2006, 1209 adults (mean age 41 years, BMI 34 
kg/m2) were screened. A total of 932 adults initiated the LCD period, and 773 adults from 634 
families were randomized to the 5 different diets. 546 adults (71%) remained at the end of 
the intervention period. After removal of cases lacking one or more hsCRP values, a data set 
of 487 adult subjects remained and will be referred to in the completion analysis. 
The dropout rates in the LGI- and HP-groups were slightly lower than in the HGI/LP-group 
(29.8% and 30.6%, respectively, vs. 42.6%; P=0.007 and P=0.013 for both comparisons, 
respectively). The risk of dropout was lower in the LGI-group compared to HGI (odds ratio, 
0.70; 95% CI, 0.50 to 0.98; P=0.036) and there was a trend to a lower risk for dropout in the 
HP- vs. LP-group (odds ratio, 0.75; 95% CI, 0.54 to 1.05; P=0.089).  
 
Dietary intake 
Detailed information on the distribution of energy intake from protein, carbohydrates, 
saturated fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids for the 
different diet groups is given in Supplemental Table 3 and Supplemental Figure 5A-B. In the 
HP groups the amount of total energy consumed from protein was 5.4 percentage points 
higher and the amount of total energy consumed from carbohydrates was 6.7 percentage 
points lower than in the LP groups (P<0.001, respectively). In the HGI groups the mean GI 
was 5.1 units higher than in the LGI groups (P<0.001).  
The participants adhered to the diet as was shown in detail previously.4 
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Supplemental Table 1. Characteristics of participants at beginning of the diet intervention period and changes between start of the low-calorie-diet (LCD) phase and randomization for the 
diet intervention.* 
Variable 
No. of 
Participants 
Low Protein 
(N=179) 
High Protein 
(N=204) 
Control 
(N=104) 
P-Value 
(Diet) 
Total 
(N=487) 
         
 
 
Low Glycemic Index 
(N = 95) 
High Glycemic Index
(N = 84) 
Low Glycemic Index 
(N = 108) 
High Glycemic Index
(N = 96)    
         
Age (yr) 487 42.1 ± 5.8 41.6 ± 5.9 42.6 ± 6.3 42.2 ± 5.6 42.8 ± 6.7 0.670 42.3± 6.1 
Height (cm) 487 170.5 ± 10.0 169.6 ± 7.8 170.5 ± 9.9 171.5 ± 9.8 169.9 ± 9.0 0.896 170.4± 0.1 
Body weight (kg)          
Mean 487 89.0 ± 15.8 86.1 ± 13.1 88.1 ± 14.6 88.7 ± 17.3 87.8 ± 16.4 0.598 88.0± 15.5 
Mean change during LCD phase 487 -11.5 ± 3.4 -10.6 ± 3.5 -11.2 ± 3.4 -11.2 ± 3.0 -11.5 ± 4.1 0.578 -11.2± 3.5 
Waist circumference (cm)          
Mean 477 96.7 ± 11.7 95.8 ± 10.5 96.5 ± 10.9 97.4 ± 13.6 96.8 ± 12.3 0.905 96.7± 11.9 
Mean change during LCD phase 477 -10.5 ± 4.9 -9.6 ± 4.7 -9.8 ± 4.7 -10.0 ± 4.8 -9.8 ± 5.3 0.977 -9.9± 4.9 
hsCRP (mg/L)          
Mean 487 2.96 ± 3.11 2.96 ± 2.84 2.93 ± 2.73 2.29 ± 1.94 2.50 ± 2.17 0.800 2.78± 2.63 
Mean change during LCD phase 487 -1.41 ± 5.55 -0.87 ± 3.55 -1.29 ± 2.84 -1.23 ± 2.90 -0.92 ± 1.76 0.703 -1.15± 3.49 
Cholesterol (mmol/L)          
Mean 487 4.14 ± 0.91 4.12 ± 0.92 4.17 ± 0.87 4.21 ± 0.98 4.13 ± 0.88 0.987 4.16± 0.91 
Mean change during LCD phase 480 -0.64 ± 0.85 -0.74 ± 0.68 -0.67 ± 0.76 -0.64 ± 0.73 -0.76 ± 0.64 0.785 -0.69± 0.74 
HDL (mmol/L)          
Mean 487 1.13 ± 0.28 1.17 ± 0.25 1.16 ± 0.29 1.14 ± 0.27 1.21 ± 0.26 0.105 1.16± 0.27 
Mean change during LCD phase 482 -0.09 ± 0.25 -0.08 ± 0.21 -0.07 ± 0.23 -0.04 ± 0.20 -0.08 ± 0.23 0.253 -0.07± 0.23 
LDL (mmol/L)          
Mean 485 2.54 ± 0.76 2.42 ± 0.79 2.54 ± 0.81 2.56 ± 0.81 2.49 ± 0.80 0.853 2.51± 0.78 
Mean change during LCD phase 478 -0.45 ± 0.69 -0.57 ± 0.60 -0.46 ± 0.65 -0.46 ± 0.64 -0.53 ± 0.56 0.611 -0.49± 0.63 
Triglycerides (mmol/L)          
Mean 484 1.06 ± 0.48 1.08 ± 0.55 1.03 ± 0.40 1.05 ± 0.42 0.95 ± 0.34 0.234 1.03± 0.44 
Mean change during LCD phase 482 -0.64 ± 0.85 -0.74 ± 0.68 -0.67 ± 0.76 -0.65 ± 0.73 -0.76 ± 0.64 0.785 -0.69± 0.74 
Systolic Blood Pressure (mmHg)          
Mean 477 118.6 ± 13.7 115.5 ± 13.9 118.8 ± 13.3 120.1 ± 15.0 116.8 ± 14.1 0.716 118.0± 14.0 
Mean change during LCD phase 469 -7.0 ± 10.1 -8.0 ± 10.1 -7.6 ± 12.0 -8.3 ± 13.1 -7.4 ± 11.4 0.918 -7.7± 11.5 
Diastolic Blood Pressure (mmHg)          
Mean 477 73.9 ± 9.4 71.4 ± 9.2 73.5 ± 9.6 73.4 ± 10.3 70.9 ± 10.1 0.428 72.6± 9.8 
Mean change during LCD phase 469 -4.3 ± 8.0 -5.1 ± 7.6 -5.5 ± 8.1 -5.7 ± 8.7 -7.1 ± 11.4 0.340 -5.6± 8.9 
Fasting Insulin (mU/L)          
Mean 422 10.17 ± 15.95 7.15 ± 4.10 6.51 ± 3.56 7.97 ± 6.12 8.04 ± 9.35 0.273 7.95± 9.05 
Mean change during LCD phase 407 -3.39 ± 7.33 -3.35 ± 3.99 -4.15 ± 5.02 -5.66 ± 13.04 -3.99 ± 6.65 0.393 -4.14± 7.93 
Insulin 120 min OGTT (mU/L)          
Mean 473 56.74 ± 42.81 50.78 ± 27.73 46.55 ± 24.80 52.11 ± 39.57 50.07 ± 31.19 0.643 51.09± 33.78 
Mean change during LCD phase 465 -15.32 ± 45.25 -10.86 ± 40.67 -20.87 ± 36.10 -16.73 ± 37.37 -16.01 ± 44.45 0.431 -16.23± 40.84 
Fasting Glucose (mmol/L)          
Mean 478 4.88 ± 0.63 4.69 ± 0.44 4.84 ± 0.55 4.83 ± 0.73 4.80 ± 0.53 0.252 4.81± 0.59 
Mean change during LCD phase 463 -0.33 ± 0.65 -0.18 ± 0.57 -0.27 ± 0.67 -0.22 ± 0.84 -0.27 ± 0.51 0.119 -0.26± 0.65 
Glucose 120 min OGTT (mmol/L)          
Mean 467 6.84 ± 2.07 6.75 ± 2.06 6.94 ± 2.10 6.70 ± 2.02 6.62 ± 1.76 0.310 6.77± 2.00 
Mean change during LCD phase 451 0.17 ± 2.14 0.37 ± 1.90 0.14 ± 1.98 0.14 ± 0.84 0.05 ± 1.65 0.891 0.17± 1.92 
* Values shown are means ± SD. Those participants of the study were included into this analysis, who completed the diet intervention period and had complete records for hsCRP at beginning of the 
low-calorie-diet phase and at the time of randomization. 
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Supplemental Table 2. Linear mixed models, fixed factors, random variables and P-values for all endpoints. 
Endpoint Regression-Model Fixed Random P-Value for diet-term 
Common 
௧ܻ௜ ൌ ߚଵ ൈ ܺ௧௜
ሺଵሻ ൅ ߚଶ ൈ ܺ௧௜
ሺଶሻ ൅ ߚଷ ൈ ܺ௧௜
ሺଷሻ ൅ ڮ൅ ߚ௣ ൈ ܺ௧௜
ሺ௣ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑଵ௜ ൈ ܼ௧௜
ሺଵሻ ൅ ڮ൅ ݑ௤௜ ൈ ܼ௧௜
ሺ௤ሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
   
hsCRP 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚௗ௜௘௧כ௖௘௡௧௘௥ ൈ ܺ௧௜
ሺௗ௜௘௧כ௖௘௡௧௘௥ሻ ൅ ߚௗ௜௘௧כ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺௗ௜௘௧כ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௖௥௣ଶכ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௖௥௣ଶכ௔௚௘ሻ ൅ ݑ௖௥௣ଶכ௪௘௜௚௛௧ଶǡ௜ ൈ ܼ௧௜
ሺ௖௥௣ଶכ௪௘௜௚௛௧ଶሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
diet*centera) 
diet*gender 
crp2*ageb) 
crp2*weight2
GI: <0.001 
Prot: <0.001 
Total: <0.001 
Cholesterol 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௔௚௘ሻ ൅ ݑ௪௘௜௚௛௧ଶǡ௜ ൈ ܼ௧௜
ሺ௪௘௜௚௛௧ଶሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
center*gender 
age 
weight2c) 
GI: 0.725 
Prot: 0.828 
Total: 0.703 
HDL-Cholesterol 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௔௚௘ሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
gender age 
GI: 0.900 
Prot: 0.685 
Total: 0.593 
LDL-Cholesterol 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௔௚௘ሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
gender age 
GI: 0.926 
Prot: 0.898 
Total: 0.730 
Triglycerides 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௣௔௥௧௡௘௥ ൈ ܺ௧௜
ሺ௖௘௡௧௘௥ሻ ൅ ߚ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௪௘௜௚௛௧ଶǡ௜ ൈ ܼ௧௜
ሺ௪௘௜௚௛௧ଶሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
center 
gender 
weight2 
 
GI: 0.966 
Prot: 0.691 
Total: 0.832 
Systolic Blood Pressure 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௔௚௘ሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
center*gender age 
GI: 0.668 
Prot: 0.159 
Total: 0.556 
Diastolic Blood Pressure 
௧ܻ௜ ൌ ߚௗ௜௘௧ ൈ ܺ௧௜
ሺௗ௜௘௧ሻ ൅ ߚ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ ൈ ܺ௧௜
ሺ௖௘௡௧௘௥כ௚௘௡ௗ௘௥ሻቅ ࢌ࢏࢞ࢋࢊ 
൅ݑ௔௚௘ǡ௜ ൈ ܼ௧௜
ሺ௔௚௘ሻ ൅ ߝ௧௜ቅ ࢘ࢇ࢔ࢊ࢕࢓ 
 
diet 
center*gender age 
GI: 0.492 
Prot: 0.363 
Total: 0.098 
a) Center: index of center where participants took part in the study; b) crp2: hsCRP at randomization; c) weight2: body weight at randomization 
GI: high or low glycemic index; Prot: high or low protein; Total: LGI/LP, LGI/HP, HGI/LP, HGI/HP or control diet; 
Yti: predicted value of outcome variable at time-point t for the i-th participant; Xti: measured value of a fixed factor at time-point t for the i-th participant; Ep: regression 
term of the p-th fixed factor; Zti: measured value of a random effect at time-point-t for the i-th participant; uqi: regression term of the q-th random effect for the i-th 
participant; Hti: residual at time-point t for the i-th participant. 
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Supplemental Table 3. Energy and nutrient intake between screening and week 26 of the diet intervention period.* 
Variable Low Protein High Protein Control 
      
 Low Glycemic Index High Glycemic Index Low Glycemic Index High Glycemic Index  
             
 
no. of 
participants intake 
no. of 
participants intake 
no. of 
participants intake 
no. of 
participants intake 
no. of 
participants intake 
            
Energy and nutrient intake            
Energy (kj/day)            
At screening 90 9075 ± 3388 75 9752 ± 3529 102 9657 ± 2868 90 9492 ± 3311 95 9843 ± 2924 
Change from screening to wk 26 67 -2218 ± 3734 52 -2046 ± 3210 82 -2259 ± 2759 67 -2609 ± 2603 72 -2350 ± 3401 
Carbohydrates (% of total energy intake)            
At screening 90 42.2 ± 9.0 75 44.7 ± 8.6 102 43.7 ± 8.8 90 45.2 ± 7.3 95 43.7 ± 8.4 
Change from screening to wk 26 67 9.0 ± 8.6 52 6.0 ± 10.1 82 1.4 ± 10.7 67 0.5 ± 7.4 72 2.8 ± 9.1 
Total fat (% of total energy intake)            
At screening 90 37.4 ± 7.8 75 36.3 ± 7.4 102 36.1 ± 7.5 90 36.3 ± 6.7 95 36.5 ± 6.8 
Change from screening to wk 26 67 -7.7 ± 8.8 52 -5.5 ± 10.4 82 -4.9 ± 9.6 67 -5.9 ± 8.1 72 -3.4 ± 9.1 
Saturated fat (% of total energy intake)            
At screening 80 13.2 ± 4.2 70 12.6 ± 3.8 89 12.7 ± 3.9 80 12.8 ± 3.9 84 12.6 ± 4.2 
Change from screening to wk 26 57 -5.1 ± 5.5 47 -3.9 ± 6.0 70 -4.5 ± 6.2 58 -6.0 ± 5.0 62 -4.0 ± 6.0 
Monounsaturated fat (% of total energy intake)            
At screening 80 12.4 ± 5.5 70 10.8 ± 4.6 89 11.0 ± 4.7 80 11.6 ± 5.2 83 11.1 ± 4.3 
Change from screening to wk 26 57 -5.0 ± 6.7 47 -3.1 ± 5.5 70 -3.1 ± 5.3 58 -4.6 ± 5.6 62 -4.0 ± 5.5 
Polyunsaturated fat (% of total energy intake)            
At screening 80 8.4 ± 5.5 70 8.0 ± 5.6 89 7.7 ± 4.7 80 7.8 ± 4.7 83 8.1 ± 4.8 
Change from screening to wk 26 57 -2.7 ± 5.8 47 -2.1 ± 4.6 70 -2.2 ± 4.4 58 -2.7 ± 3.7 62 -2.7 ± 4.7 
Protein (% of total energy intake)            
At screening 90 18.3 ± 5.2 75 17.0 ± 4.0 102 17.5 ± 4.0 90 16.0 ± 3.6 95 16.5 ± 4.2 
Change from screening to wk 26 67 -0.3 ± 4.7 52 -0.7 ± 4.9 82 4.2 ± 4.5 67 6.4 ± 6.0 72 1.8 ± 5.1 
Glycemic index            
At screening 90 61.0 ± 5.7 75 60.7 ± 4.7 102 61.1 ± 5.2 90 61.4 ± 4.4 95 61.3 ± 4.9 
Change from screening to wk 26 67 -4.7 ± 6.8 52 0.3 ± 5.6 82 -4.9 ± 6.9 67 0.3 ± 6.0 72 -2.6 ± 6.2 
* Values shown are means ± SD. Participants were included in this analysis if they had completed the diet intervention period and had complete records for hsCRP at the beginning (randomization) and the 
end of the diet intervention period. 
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Legends to Supplemental Figures 
 
Supplemental Figure 1: Relative changes (%) of hsCRP between post-LCD (week 0) and 
post-intervention (week 26) (A). The values were normalized to post-LCD. For absolute 
values see Supplemental Table 1 and Table 2. Relative (%) changes of hsCRP between 
post-LCD (week 0) and post-intervention (week 26) (B) for the combined low GI diets 
(HP/LGI and LP/LGI) vs. high GI diets (HP/HGI and LP/HGI) and for the combined high 
protein (HP/HGI and HP/LGI) vs. the low protein diets (LP/LGI and LP/HGI). 
 
Supplemental Figure 2: Relative changes (%) of triglycerides (A) and total cholesterol (B) on 
the different diets between pre-LCD (week 8), post-LCD (week 0) and post-intervention 
(week 26). The values were normalized to post-LCD. 
 
Supplemental Figure 3: Relative changes (%) of HDL-cholesterol (A) and  LDL-cholesterol 
(B) on the different diets between pre-LCD (week 8), post-LCD (week 0) and post-
intervention (week 26). The values were normalized to post-LCD. 
 
Supplemental Figure 4: Relative changes (%) of systolic (A) and diastolic (B) blood pressure 
on the different diets between pre-LCD (week 8), post-LCD (week 0) and post-intervention 
(week 26). The values were normalized to post-LCD. 
 
Supplemental Figure 5: (A) Protein intake of the participants at week 4 of the intervention 
and post-intervention (week 26) shown for the combined low protein (LP/HGI and LP/LGI) vs. 
the combined high protein diets (HP/LGI and HP/HGI). (B) GI of consumed carbohydrates at 
week 4 of the intervention and post-intervention (week 26) shown for the combined low GI 
diets (HP/LGI and LP/LGI) vs. the combined high GI diets (HP/HGI and LP/HGI). 
 
Supplemental Figure 6: Forest diagrams of triglycerides, LDL-cholesterol, HDL-cholesterol, 
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total cholesterol, hsCRP, fasting glucose, glucose at 120 min of oral glucose tolerance test 
(OGTT), fasting insulin, insulin at 120 min of OGTT, diastolic blood pressure, systolic blood 
pressure, sagittal diameter, hip circumference, waist circumference, fat mass, fat-free mass 
and body weigth. For absolute values refer to Table 2 of the main manuscript. 
 
Supplemental Figure 7: Parameters of glucose metabolism pre-LCD (CID1), post-LCD 
(CID2) and post-intervention (CID3). (A) Fasting glucose, (B) glucose at 120 min of OGTT, 
(C) fasting insulin, and (D) insulin at 120 min of OGTT. None of these parameters indicates 
hyperglycemic states or impaired glucose tolerance of the participants.
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Supplemental Figure 1 
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Supplemental Figure 2 
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Supplemental Figure 3 
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Supplemental Figure 4 
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Supplemental Figure 5A. Protein intake of participants at week 4 and post-intervention 
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Supplemental Figure 5B. GI of consumed carbohydrates at week 4 and post-intervention 
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Supplemental Figure 6. Forest diagrams of parameters shown in Table 2. 
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Supplemental Figure 7. Paramteres of glucose metabolism
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